FORT WORTH, Texas, Feb. 2, 2021 /PRNewswire/ -- Galderma announces that the U.S. Food and Drug Administration (FDA) has approved Restylane ® Defyne for the augmentation and correction of mild to ...

Results showed that 74% of Restylane Defyne-treated patients achieved significantly improved chin projection for up to 1 year. The Food and Drug Administration (FDA) has approved Restylane ® Defyne ...

Hyaluronic acid 20mg/mL, lidocaine 3mg/mL; injectable gel implant. Should only be used by trained and experienced healthcare practitioners. Obtain patient's complete medical history prior to ...

There's a new filler in town (actually, two new fillers) and they're billed as the next big thing in the fight against laugh lines. Galderma, the pharmaceutical company behind injectables like ...

Galderma announced it has received FDA approval of two new Restylane products for the treatment of nasolabial folds in patients over the age of 21. The agency approved Restylane Refyne for moderate-to ...

LAUSANNE, Switzerland--(BUSINESS WIRE)--Galderma will present a range of new scientific data on its portfolio on their hyaluronic acid dermal filler range, their first liquid neuromodulator and their ...

The FDA has approved Restylane Defyne for mild to moderate chin retrusion augmentation in adults older than 21 years, Galderma announced in a press release. A hyaluronic acid dermal filler, Restylane ...

(MENAFN- PR Newswire) FORT WORTH, Texas, Feb. 2, 2021 /PRNewswire/ -- Galderma announces that the U.S. Food and Drug Administration (FDA) has approved Restylane® Defyne for the augmentation and ...